Several effective inhibitors of VEGFR-2 have been developed and approved as antiangiogenic agents for different cancer medicines, for example, pazopanib (V) [25,26] and sorafenib (Nexavar)® (VI) [27,28,29] (Figure 1). The gene discussed is KDR; the disease is cancer.